Vitamin D supplementation reduces liver inflammation and fibrosis largely through TXNIP

Chronic liver disease (CLD) is a major global health concern, affecting approximately 1.5 billion people. This life-threatening disease often progresses silently, eventually leading to worsened conditions like liver cirrhosis or liver cancer. There is currently no treatment for CLD other than liver transplantation.

Vitamin D is commonly consumed for enhanced bone health. This study opens exciting possibilities for repurposing an inexpensive supplement as a complementary therapy for liver diseases. Prof. Hyo-Jung Kwon from the College of Veterinary Medicine, Chungnam National University in Daejeon, Republic of Korea, and his colleagues have studied the underlying mechanisms and therapeutic implications of Vitamin D in liver disease. "Here, we explored the effects of vitamin D on ductular reaction and CLDs, and investigated underlying mechanisms. Our data reveal that vitamin D supplementation ameliorates ductular reaction and reduces liver inflammation and fibrosis largely through TXNIP," comments Prof. Kwon. Their study was published online on 13 May 2025, in Nature Communications.

Ductular reaction refers to the proliferation of ductular cells (primarily cholangiocytes) in response to liver injury. While initially protective, excessive or prolonged ductular reaction contributes to inflammation and fibrosis. In this study, researchers observed that lower plasma levels of vitamin D were associated with more severe ductular reaction in patients with CLD.

Vitamin D upregulates the expression of TXNIP (Thioredoxin-interacting protein). This was confirmed in a mouse study where Txnip deletion in cholangiocytes promoted ductular reaction and even exacerbated liver inflammation and fibrosis. In vitro analysis revealed the Vitamin D/TXNIP molecular axis. "Furthermore, Txnip deficiency increases TNF-α and TGF-β secretion by cholangiocytes to stimulate Kupffer cells and hepatic stellate cells, consequently leading to inflammation and collagen deposition," adds Prof. Kwon.

Research that supports early diagnosis and better treatment for CLD is not only warranted but essential. "Our preclinical data reveal a new mechanism by which vitamin D supplementation ameliorates CLDs and support the idea that the vitamin D/TXNIP axis could be a promising therapeutic target in clinically addressing the ductular reaction and CLDs," comments Prof. Kwon.  Further research is needed to validate the clinical application of vitamin D supplementation as a standard supportive therapy for patients with chronic liver disease.

Ultimately, this work could improve outcomes for millions worldwide by offering safer and more personalized liver disease therapies.

Source:
Journal reference:

Baek, E. B., et al. (2025). Vitamin D supplementation ameliorates ductular reaction, liver inflammation and fibrosis in mice by upregulating TXNIP in ductular cells. Nature Communications. doi.org/10.1038/s41467-025-59724-z.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Heavy drinking now poses greater liver disease risk than two decades ago